Abstract:The demethylation metabolism of natural drugs which were difficult to absorb through the gut microbiota was first reported.The use of computer-assisted drug design and metabolism research techniques in vivo and in vitro is significant to explain the metabolic transformation mechanism of natural isoquinoline alkaloids in vivo.A new idea for studying the drug metabolism mechanism of gut microbiota was provided by using the specific inhibitor of CYP51.Berberine (BBR) is an isoquinoline alkaloid extracted from Coptis chinensis that improves diabetes, hyperlipidemia and inflammation. Due to the low oral bioavailability of BBR, its mechanism of action is closely related to the gut microbiota. This study focused on the CYP51 enzyme of intestinal bacteria to elucidate a new mechanism of BBR transformation by demethylation in the gut microbiota through multiple analytical techniques. First, the docking of BBR and CYP51 was performed; then, the pharmacokinetics of BBR were determined in ICR mice in vivo, and the metabolism of BBR in the liver, kidney, gut microbiota and single bacterial strains was examined in vitro. Moreover, 16S rRNA analysis of ICR mice feces indicated the relationship between BBR and the gut microbiota. Finally, recombinant E. coli containing cyp51 gene was constructed and the CYP51 enzyme lysate was induced to express. The metabolic characteristics of BBR were analyzed in the CYP51 enzyme lysate system. The results showed that CYP51 in the gut microbiota could bind stably with BBR, and the addition of voriconazole (a specific inhibitor of CYP51) slowed down the metabolism of BBR, which prevented the production of the demethylated metabolites thalifendine and berberrubine. This study demonstrated that CYP51 promoted the demethylation of BBR and enhanced its intestinal absorption, providing a new method for studying the metabolic transformation mechanism of isoquinoline alkaloids in vivo.<ol class="links-for-figure"><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S2095177920310728-fx1_lrg.jpg">Download : Download high-res image (208KB)</a></li><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S2095177920310728-fx1.jpg">Download : Download full-size image</a></li></ol>

Transformation of berberine to its demethylated metabolites by the CYP51 enzyme in the gut microbiota

Transforming berberine into its intestine-absorbable form by the gut microbiota

Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine

CYP450 1A2 and multiple UGT1A isoforms are responsible for jatrorrhizine metabolism in human liver microsomes.

Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR’s cholesterol-decreasing efficacy in patients

The mechanism of berberine alleviating metabolic disorder based on gut microbiome

Berberine influences multiple diseases by modifying gut microbiota

The metabolism of berberine and its contribution to the pharmacological effects

Molecular mechanisms, targets and clinical potential of berberine in regulating metabolism: a review focussing on databases and molecular docking studies

Berberine-microbiota interplay: orchestrating gut health through modulation of the gut microbiota and metabolic transformation into bioactive metabolites

Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: Part 1. Physicochemical and pharmacokinetic properties

Multi-Pharmacology of Berberine in Atherosclerosis and Metabolic Diseases: Potential Contribution of Gut Microbiota

Berberine Effect of Anti-microbiota-Possibility and Clinical Significance on Gut Microbiota and Metabolism: A Review

Modulation of Gut Microbiota and Metabolites by Berberine in Treating Mice With Disturbances in Glucose and Lipid Metabolism

UPLC-Q-TOFMS/MS Analysis of Berberine and Gut Microbiota Transformed Metabolites

Biodistribution and pharmacokinetic profile of berberine and its metabolites in hepatocytes

Effect of Gut Microbiota on the Metabolism of Chemical Constituents of Berberis kansuensis Extract Based on UHPLC-Orbitrap-MS Technique

Responses of human gut microbiota abundance and amino acid metabolism in vitro to berberine

Biotransformation of Modified Benzylisoquinoline Alkaloids: Boldine and Berberine and In Silico Molecular Docking Studies of Metabolites on Telomerase and Human Protein Tyrosine Phosphatase 1B

The Gut-Related Mechanisms of Berberine in the Treatment of Metabolic Diseases

Comprehensive insights into berberine's hypoglycemic mechanisms: A focus on ileocecal microbiome in db/db mice